
Contributions
Abstract: P439
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Immunology
Objective: We study the subsets of T and B lymphocytes present in the active and remission phases of anti-myelin oligodendrocyte glycoprotein (MOG)-related disorder (MOG-RD) and anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). In this study, the subsets of
T and B cells in peripheral blood were compared in patients in remission.
Patients and methods: Peripheral blood was collected from 5 and 12 patients who had been treated for acute MOG-RD and AQP4-NMOSD, respectively, ≥1 month earlier and were presently in remission. The levels of anti-MOG and anti-AQP4 antibodies was measured by the Department of Neurology, Tohoku University School of Medicine. Without removing red blood cells, 2 ml peripheral blood was subjected to staining of various T- and B-cell surface markers and flow cytometry using BD FACSCanto II (Becton, Dickinson and Company). T cells examined in this study were CD8+ CD11b− cytotoxic T cells, activated CD4 (CD4+ HLA+) T cells, activated CD8 (CD8+ HLA+) T cells, CD4+ CD25high regulatory T cells, and CD3− CD16/56+ natural killer cells. B cells examined were CD19+ CD27+ CD38high CD180− plasmablasts, CD19+ CD27+ memory B cells, CD19+ CD27− naive B cells, and CD19+ CD24high CD38high transitional B cells.
Results: No significant difference in T cell subsets was observed between the two disorders. As for B cell subsets, the level of plasmablasts was significantly higher in patients with AQP4-NMOSD (1.9±1.72) than in those with MOG-RD (0.74±0.62), whereas no significant difference was observed in transitional, naive, and memory B cells.
Conclusion: Plasmablasts might be involved in the pathology of AQP4-NMOSD, but not MOG-RD, even in the remission phase.
Disclosure: nothing
Abstract: P439
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Immunology
Objective: We study the subsets of T and B lymphocytes present in the active and remission phases of anti-myelin oligodendrocyte glycoprotein (MOG)-related disorder (MOG-RD) and anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD). In this study, the subsets of
T and B cells in peripheral blood were compared in patients in remission.
Patients and methods: Peripheral blood was collected from 5 and 12 patients who had been treated for acute MOG-RD and AQP4-NMOSD, respectively, ≥1 month earlier and were presently in remission. The levels of anti-MOG and anti-AQP4 antibodies was measured by the Department of Neurology, Tohoku University School of Medicine. Without removing red blood cells, 2 ml peripheral blood was subjected to staining of various T- and B-cell surface markers and flow cytometry using BD FACSCanto II (Becton, Dickinson and Company). T cells examined in this study were CD8+ CD11b− cytotoxic T cells, activated CD4 (CD4+ HLA+) T cells, activated CD8 (CD8+ HLA+) T cells, CD4+ CD25high regulatory T cells, and CD3− CD16/56+ natural killer cells. B cells examined were CD19+ CD27+ CD38high CD180− plasmablasts, CD19+ CD27+ memory B cells, CD19+ CD27− naive B cells, and CD19+ CD24high CD38high transitional B cells.
Results: No significant difference in T cell subsets was observed between the two disorders. As for B cell subsets, the level of plasmablasts was significantly higher in patients with AQP4-NMOSD (1.9±1.72) than in those with MOG-RD (0.74±0.62), whereas no significant difference was observed in transitional, naive, and memory B cells.
Conclusion: Plasmablasts might be involved in the pathology of AQP4-NMOSD, but not MOG-RD, even in the remission phase.
Disclosure: nothing